Emicizumab for acquired haemophilia A: A case series.

Background: Emicizumab is approved to prevent bleeding in patients with congenital haemophilia A with or without inhibitors. However, no randomized trials addressed the efficacy of emicizumab in acquired haemophilia A (AHA).

Aims: To report the clinical and biochemical response of emicizumab in AHA.